BRIEF - Shionogi signs up to Ube research deal

Japanese pairing Shionogi and Ube Industries have agreed to jointly research respiratory syncytial virus (RSV) drug candidates.

Based on Shionogi’s drug discovery in the infectious disease area and Ube Industries’ drug design supported by organic synthesis capabilities, the partnership will strive to provide best possible anti-RSV drugs to patients as early as possible, combining the firms’ strengths in generating drug candidates.

There are currently no anti-RSV products available.